1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Hangzhou Unogen Biotech Ltd. has 1 pending office action currently under review. This action is handled by 1 distinct examiner, OUSPENSKI, ILIA I, who is the busiest examiner for the company with 1 busiest examiner pending action. The data shows 0 distinct art units associated with this activity, which indicates a notable administrative footprint.
Because there is only 1 pending office action, the company's current prosecution experience is defined by the interaction with OUSPENSKI, ILIA I. The lack of multiple examiners or art units suggests that the success of the company's current patenting efforts depends entirely on this single examiner's review. The 1 busiest examiner pending action is the only active matter for the company at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294406 | ANTI-CD38 ANTIBODIES, ANTI-CD3 ANTIBODIES, AND BISPECIFIC ANTIBODIES, AND USES THEREOF | OUSPENSKI, ILIA I | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294406 | ANTI-CD38 ANTIBODIES, ANTI-CD3 ANTIBODIES, AND BISPECIFIC ANTIBODIES, AND USES THEREOF | OUSPENSKI, ILIA I | — | §112 | Non-Final OA | — | Pending | Feb 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Unogen Biotech Ltd. has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Ilia I Ouspenski has the most, with 1 of Hangzhou Unogen Biotech Ltd.'s pending office actions.
